Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ASMB 
Assembly Biosciences Inc (ASMB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: ASMB (1-star) is a SELL. SELL since 1 days. Simulated Profits (-11.04%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $38.25
1 Year Target Price $38.25
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 46.41% | Avg. Invested days 36 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 339.99M USD | Price to earnings Ratio - | 1Y Target Price 38.25 |
Price to earnings Ratio - | 1Y Target Price 38.25 | ||
Volume (30-day avg) 2 | Beta 0.69 | 52 Weeks Range 7.75 - 27.17 | Updated Date 09/15/2025 |
52 Weeks Range 7.75 - 27.17 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -117.2% | Operating Margin (TTM) -115.24% |
Management Effectiveness
Return on Assets (TTM) -27.74% | Return on Equity (TTM) -147.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 95542902 | Price to Sales(TTM) 10.23 |
Enterprise Value 95542902 | Price to Sales(TTM) 10.23 | ||
Enterprise Value to Revenue 2.87 | Enterprise Value to EBITDA 0.42 | Shares Outstanding 7672260 | Shares Floating 3593610 |
Shares Outstanding 7672260 | Shares Floating 3593610 | ||
Percent Insiders 38.52 | Percent Institutions 25.43 |
Upturn AI SWOT
Assembly Biosciences Inc
Company Overview
History and Background
Assembly Biosciences, Inc. was founded in 2005. It's a biotechnology company focused on developing and commercializing novel therapeutics targeting hepatitis B virus (HBV) infection and other viral diseases.
Core Business Areas
- HBV Program: Focused on developing a core inhibitor platform to treat HBV infection. This includes researching and developing novel compounds that disrupt the HBV replication cycle.
Leadership and Structure
The leadership team typically consists of a CEO, CFO, CSO, and other VPs heading various departments (R&D, Clinical Development, etc.). The organizational structure is a typical biotechnology setup with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- Vebicorvir (ABI-H0731): An investigational core inhibitor for the treatment of chronic HBV infection. Currently in clinical trials. Competitors include Gilead Sciences (Vemlidy) and other companies developing novel HBV therapies.
- ABI-4334: Next-generation HBV core inhibitor. Currently in Phase 1a studies. Competitors: Developing pipeline therapies from other biotech and pharma companies.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the antiviral segment, is highly competitive and regulated. There is significant unmet need for more effective and curative treatments for chronic HBV infection.
Positioning
Assembly Biosciences is positioned as an innovator in the HBV therapeutic area, focusing on developing core inhibitors that offer a novel mechanism of action. Their competitive advantage lies in their core inhibitor platform and potential to achieve functional cure.
Total Addressable Market (TAM)
The global hepatitis B therapeutics market is estimated to be several billion USD annually. Assembly Biosciences is targeting a portion of this market by developing a functional cure which would significantly expand the treatable population.
Upturn SWOT Analysis
Strengths
- Novel core inhibitor platform
- Experienced management team
- Strong intellectual property position
- Clinical trial progress
Weaknesses
- High R&D expenses
- Dependence on clinical trial outcomes
- Limited revenue
- Cash burn rate
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of core inhibitor platform to other viral diseases
- Positive clinical trial results
- Regulatory approval of vebicorvir
Threats
- Clinical trial failures
- Competition from other HBV therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- GILD
- JNJ
- ABBV
Competitive Landscape
Assembly Biosciences competes with larger pharmaceutical companies in the HBV market. Its core inhibitor platform offers a differentiated approach, but clinical success and regulatory approval are crucial for long-term competitiveness.
Growth Trajectory and Initiatives
Historical Growth: Assembly Biosciences' growth has been primarily driven by progress in clinical trials and expansion of its pipeline.
Future Projections: Future growth is dependent on clinical trial success, regulatory approvals, and potential partnerships. Analyst estimates vary based on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include advancing vebicorvir through clinical trials, developing next-generation core inhibitors, and seeking partnerships.
Summary
Assembly Biosciences is a clinical-stage biotechnology company focused on developing novel HBV therapies. The company's core inhibitor platform represents a promising approach, but success depends on positive clinical trial results and regulatory approvals. While the market has significant potential, Assembly Biosciences faces competition from larger pharmaceutical companies. Its future growth relies heavily on the advancement of its pipeline and strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Assembly Biosciences Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2010-12-17 | CEO, President & Director Mr. Jason A. Okazaki J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 73 | Website https://www.assemblybio.com |
Full time employees 73 | Website https://www.assemblybio.com | ||
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study. The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.